4//SEC Filing
Skolnick Phil 4
Accession 0001385508-20-000015
CIK 0001385508other
Filed
Jan 8, 7:00 PM ET
Accepted
Jan 9, 4:12 PM ET
Size
12.9 KB
Accession
0001385508-20-000015
Insider Transaction Report
Form 4
Skolnick Phil
Chief Scientific Officer
Transactions
- Award
Common Stock
2020-01-07+4,150→ 10,035 total - Sale
Common Stock
2020-01-07$13.36/sh−3,043$40,654→ 4,150 total - Sale
Common Stock
2020-01-07$13.60/sh−2,900$39,440→ 5,885 total - Sale
Common Stock
2020-01-08$13.46/sh−2,842$38,253→ 7,193 total - Award
Common Stock
2020-01-07+8,250→ 8,250 totalExercise: $13.60Exp: 2030-01-07→ Common Stock (8,250 underlying)
Footnotes (5)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $13.60 to $13.63. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]4,150 shares are represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of Issuer, subject to the vesting schedule. One-fourth of the RSUs vest on the anniversary dates of January 7, 2021, January 7, 2022, January 7, 2023 and January 7, 2024, subject to the Reporting Person continuing as a service provider through each such date.
- [F4]This transaction was executed in multiple trades at prices ranging from $13.26 to $13.59. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]On January 7, 2020, the reporting person was granted an option to purchase 8,250 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth year anniversary of the Grant Date.
Documents
Issuer
OPIANT PHARMACEUTICALS, INC.
CIK 0001385508
Entity typeother
Related Parties
1- filerCIK 0001358116
Filing Metadata
- Form type
- 4
- Filed
- Jan 8, 7:00 PM ET
- Accepted
- Jan 9, 4:12 PM ET
- Size
- 12.9 KB